Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
JOURNALS
Start Learning
Honouring Prof. Marcus Maurer
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025 severe allergic reactions, including anaphylaxis
JOURNALS
Start Learning
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
JOURNALS
Start Learning
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
JOURNALS
Start Learning
RheumaPreg 2025: Dr. Vinod Ravindran’s Perspectives and Highlights
Clinical Phenotyping and Molecular Endotyping in Osteoarthritis - Personalised Approaches to Therapeutics: Ali Mobasheri, WCO-IOF-ESCEO 2025
JOURNALS
Start Learning
Clinical Phenotyping and Molecular Endotyping in Osteoarthritis – Personalised Approaches to Therapeutics: Ali Mobasheri, WCO-IOF-ESCEO 2025
CONFERENCE HUB
Start Learning
Efficacy of secukinumab as first-line bDMARD vs standard-of-care
JOURNALS
Start Learning
Turning your Clinical Expertise into Business Success
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset in Refractory Systemic Sclerosis
JOURNALS
Start Learning
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis

to view Favourites, Keep Notes and Track CME Credits

Favourites
A Career in Endoscopy: 5 insights from UEG Lifetime Achievement Awardee – Paul Fockens
View
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children Over 4 Years, who Weigh 15 to <30 kg
View
Advancing Rheumatology Through Innovation, Education and Patient-Centred Care: An Interview with Future Leader Dr Sham Santhanam
View
Greatest Hits of 2024
View
Advancing the Role of Bone Turnover Markers in Osteoporosis Management: Stuart Silverman, WCO-IOF-ESCEO 2025
View
Dr Vinod Ravindran joins touchREVIEWS in RMD Editorial Board – Bringing a Wealth of Knowledge in Clinical Rheumatology
View
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Muhammad Nisar, BSR 2025
View
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis
View
Bimekizumab Shows Comparable One-Year Efficacy in Male and Female axSpA Patients in Phase III BE MOBILE Trials
View
Coming soon! touchIMMUNOLOGY Future Leaders 2025
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup